

The objective tumor responses are summarized in Table 4. The response rate (RR) to the 1st line treatment was 51 %, while that in all treatment lines was 42 %, and

Table 1 Patient characteristics

Characteristics	Number of patients	(%)
Age (years)		
Median (range)	62.6	(24–83)
Sex		
Male	102	(56.4)
Female	79	(42.5)
Site of metastasis		
Liver	101	(55.8)
Lung	50	(27.6)
Lymph node	30	(16.6)
Peritoneum	24	(13.3)
Intrapelvic	10	(5.5)
Bone	9	(5.0)
Local recurrence	6	(1.7)
Line of treatment		
1st	110	(60.8)
2nd	58	(32.0)
3rd	9	(5.0)
≥4th	4	(2.2)
		(n = 81)

the disease control rate (DCR) was 88 %. There were no responders in the 3rd and 4th line treatments, but 10 of the 12 patients receiving these treatments had stable disease.

Figure 1 shows the cumulative overall survival of all patients and the median survival time (MST), which was 23.0 months. The survival curves according to treatment line are compared in Fig. 1. The MSTs of the 1st line patients and the patients with further lines of treatment were 24.2 and 20.8 months, respectively. The 1st line patients showed significantly better survival in comparison to the latter patients ($P = 0.005$).

We analyzed the association of the survival benefit with the continuation of bevacizumab beyond disease progression (progressive disease; PD) in patients who received bevacizumab-containing 1st line therapy. We analyzed the association only for the 1st line patients. The median survival times of the patients who had post-PD treatment with bevacizumab and those who had post-PD treatment without bevacizumab were 25.5 and 18.6 months, respectively (Fig. 2). There were no significant differences in survival between the group who had post-PD treatment with bevacizumab and the group who had post-PD treatment without bevacizumab ($P = 0.13$). However, the group who had post-PD treatment with bevacizumab seemed to have a longer survival time than the group who had post-PD treatment without bevacizumab.

Table 2 Combination regimens used with bevacizumab

Line of treatment	mFOLFOX6		FOLFOX4		FOLFIRI		FU/LV	
	Number of patients	(%)	Number of patients	(%)	Number of patients	(%)	Number of patients	(%)
1st line	87	(48.1)	16	(8.8)	7	(3.9)	1	(0.6)
2nd line	21	(11.6)	7	(3.9)	30	(1.7)	0	(0)
3rd line	2	(1.1)	1	(0.6)	6	(3.3)	0	(0)
≥4th line	1	(0.6)	0	(0)	1	(0.6)	1	(0.6)
Overall	111	(61.3)	24	(13.3)	44	(24.3)	2	(1.1)
		n = 181		n = 181		n = 181		n = 181

mFOLFOX6 modified FOLFOX6 (5-FU/leucovorin plus oxaliplatin), *FOLFOX4* 5-FU/leucovorin plus oxaliplatin, *FOLFIRI* 5-FU/leucovorin plus irinotecan, *FU/LV* fluorouracil/leucovorin

Table 3 The 2nd and 3rd line regimens used for patients who received bevacizumab as the 1st line treatment

Line of treatment	Regimen	Number of patients	(%)
2nd line		n = 71	
	Combination with bevacizumab	43	(61)
	Chemotherapy only	24	(34)
	Combination with cetuximab	4	(6)
3rd line		n = 22	
	Combination with bevacizumab	6	(27)
	Chemotherapy only	5	(23)
	Combination with cetuximab	11	(50)

Table 4 Objective tumor responses

Line of treatment	Clinical response				RR		DCR	
	CR	PR	SD	PD	Number of patients	(%)	Number of patients	(%)
1st line	1	45	37	7	46	51	83	92
2nd line	3	16	23	10	19	37	42	81
3rd line	0	0	7	2	0	0	7	75
≥4th line	0	0	3	0	0	0	3	100
Overall	4	61	70	19	65	42	135	88
						<i>n</i> = 154	<i>n</i> = 154	

CR complete response, PR partial response, SD stable disease, PD progressive disease, RR response rate, DCR disease control rate




Fig. 1 a Cumulative overall survivals of all patients, patients with 1st line treatment, and patients with further lines of treatment. The median survival time of all patients was 23.0 months. *1st line* 1st line patients, *≥2nd line* patients with further lines of treatment. The median survival time was 24.2 months in the 1st line patients, compared with 20.8 months in the latter patients, corresponding to a hazard ratio (*HR*) for death of 1.94 (*P* = 0.005). The mean observation time was 16.6 months. *CI* confidence interval

Tables 5 and 6 list grade 3 or greater hematological and non-hematological adverse events. The incidences of grade 3 or greater adverse events were as follows: neuropathy occurred in 33 patients (18.2 %), neutropenia in 31 patients (17.1 %), anorexia in 28 patients (15.5 %), nausea/vomiting in 26 patients (14.4 %), hypertension and diarrhea/constipation in 22 patients (12.2 %), fatigue in 18 patients (9.9 %), thrombocytopenia in 10 patients (5.5 %), coagulation abnormalities in 2 patients (1.1 %), and ischemic heart disease in 1 patient (0.6 %). Hypertension, bleeding, proteinuria, venous/arterial thrombosis, gastrointestinal (GI) perforation, wound-healing complications, and allergic reactions have often been reported as bevacizumab-related adverse events [11–14]. In our cohort, cytotoxic chemotherapy-related adverse events, such as neuropathy and neutropenia, constituted the majority of the adverse events. The most common grade 3 or greater adverse event




Fig. 2 Cumulative overall survivals in 71 patients with post-progressive disease (PD) treatment with or without bevacizumab. *Bev* post-PD treatment with bevacizumab, *No-Bev* post-PD treatment without bevacizumab. The median survival time was 25.5 months in the Bev group, compared with 18.6 months in the No-Bev group, corresponding to a hazard ratio (*HR*) for death of 1.9 (*P* = 0.13). The mean observation time was 18 months

associated with bevacizumab was hypertension. It is noteworthy that GI perforation occurred at a relatively high frequency, in 8 of the 181 patients (4.4 %). Table 7 shows the characteristics of the patients with GI perforation. The mean period from the initiation of bevacizumab to GI perforation was 25.3 days. The GI perforation occurred at the tumor site in two patients, in the colon in two patients with primary resection, and in the small intestine in the other four patients. In addition, 2 of these 8 patients had a history of abdominal/pelvic radiotherapy, 1 had had a Meckel diverticulum resection, and 3 had a history of peritoneal carcinomatosis.

Discussion

Combinations of bevacizumab with chemotherapy have shown increased efficacy compared with chemotherapy

Table 5 Grade 3 or greater hematological adverse events

Adverse event	1st Line		Overall	
	Number of patients	(%)	Number of patients	(%)
Neutropenia	18	9.9	31	17.1
Thrombocytopenia	4	2.2	10	5.5
Leukopenia	2	1.1	5	2.8
Coagulation abnormality	0	0	2	1.1

Table 6 Grade 3 or greater non-hematological adverse events

Adverse event	1st Line		Overall	
	Number of patients	(%)	Number of patients	(%)
Neuropathy	20	11.0	33	18.2
Anorexia	17	9.4	28	15.5
Nausea/vomiting	13	7.2	26	14.4
Diarrhea/constipation	10	5.5	22	12.2
Fatigue	12	6.6	18	9.9
Oral ulcer	11	6.1	15	8.3
Alopecia	8	4.4	11	6.1
Dysgeusia	5	2.8	6	3.3
Rash	3	1.7	5	2.8
Liver dysfunction	0	0	2	1.1
Fever elevation	0	0	2	1.1
Ischemic heart disease	1	0.6	1	0.6
Hypertension	12	6.6	22	12.2
GI perforation	5	2.8	8	4.4
Hemorrhage	4	2.2	8	4.4
Allergic reaction	0	0	4	2.2
Thrombosis	2	1.1	2	1.1
Wound-healing complication	1	0.6	1	0.6
Proteinuria	1	0.6	1	0.6
Other	1	0.6	4	2.2

Table 7 Characteristics of patients with gastrointestinal (GI) perforation

Case no.	Treatment line	Period from the initiation of bevacizumab to GI perforation (days)	Perforation site and details
Case 1	1	40	Tumor site, peritoneal carcinomatosis
Case 2	3	13	Tumor site
Case 3	1	27	Small intestine, peritoneal carcinomatosis
Case 4	1	6	Colon (primary resection), peritoneal carcinomatosis
Case 5	2	8	Colon (primary resection), abdominal/pelvic radiotherapy
Case 6	1	55	Small intestine, abdominal/pelvic radiotherapy
Case 7	1	28	Small intestine
Case 8	1	Not known	Small intestine, Meckel diverticulum resection

alone [8, 9, 15]. In the BEAT study, Van Cutsem et al. [13] reported the safety and efficacy of bevacizumab with various chemotherapy regimens for metastatic colorectal cancer.

The results of randomized controlled trials (RCTs) in patients with advanced colorectal cancer demonstrated that the median overall survival was 16–23 months in the patients who received bevacizumab with fluoropyrimidine-based chemotherapy, including 5-FU/folinic acid (FA), irinotecan plus 5-FU/leucovorin (IFL), 5-FU/leucovorin plus oxaliplatin (FOLFOX), and capecitabine plus oxaliplatin (XELOX), as 1st line chemotherapy [8, 9, 16]. A Japanese clinical trial of XELOX plus bevacizumab in patients with mCRC reported that the median overall survival was 27.4 months [10]. Although our analysis was based on bevacizumab combined with various regimens, the overall survivals of both the 1st line patients and the patients with further lines of treatment in our study are in no way inferior to those in the previous reports. However, our 1st line patients showed significantly better survival in comparison to the latter patients ($P = 0.005$). It is suggested that the initiation of bevacizumab in the 1st line treatment provided long-term survival.

In the BRiTE study, the authors reported that there was a survival benefit associated with the continuation of bevacizumab beyond PD in patients who received bevacizumab-containing 1st line therapy [17]. There were no significant differences in survival between the groups with and without post-PD treatment with bevacizumab in the present study. However, the group who had post-PD treatment with bevacizumab showed a longer survival time, because many patients in that group had stable disease. The benefit of continuous administration of bevacizumab beyond PD is controversial. Disclosure of the results of two prospective randomized trials (the ML18147 study and the SPIRITT study) could resolve this issue.

The incidences of grade 3 or greater adverse events related to bevacizumab reported in previous studies [8, 9, 13, 15, 17–23] were: hypertension in 3.7–11.0 % of patients, proteinuria in 0.6–0.8 %, hemorrhage in 1.9–3.1 %, wound-healing complications in 0.8–2.0 %, venous thrombosis in 3.4–7.8 %, arterial thrombosis in 1.1–1.7 %, and GI perforation in 0.7–1.7 %. In the present study, there were no differences in the incidence of bevacizumab-related grade 3 or greater adverse events compared with the findings in previous studies, except for the incidence of GI perforation. The incidence of GI perforation in our study was higher than that in the previous studies.

Some risk factors for GI perforation associated with bevacizumab have been reported in CRC patients. A univariate analysis showed that patients with intact primary tumors, a history of sigmoidoscopy or colonoscopy within 1 month of the initiation of bevacizumab therapy, or a

history of previous adjuvant radiotherapy might have an increased risk of GI perforation [24]. In addition, patients with ovarian cancer might share similar risk factors, as many have peritoneal carcinomatosis, a history of multiple surgeries, radiation exposure, and invasion of the GI tract by the tumor [25]. Most of the GI perforations in our series occurred during the early period after the initiation of bevacizumab, and these patients also had some risk factors for this complication. It is possible that the perforation events might have been directly related to the bevacizumab treatment. Therefore, identifying patients at high risk of developing a GI perforation will be an important initial step in reducing the risk of such complications. In addition, in patients receiving bevacizumab, physicians should be highly vigilant to detect any sign of perforation as early as possible.

The present study has several potential limitations because it was a retrospective analysis and a multicenter study. These factors made it difficult to obtain some detailed information. Although our survey study likely revealed the current situation in Japan, a prospective multicenter study is needed in this country.

In conclusion, this study revealed that the survival benefit of bevacizumab in Japanese patients with mCRC was similar to that observed in previous clinical trials from other countries. On the other hand, this study showed a higher incidence of GI perforation compared with findings in previous studies. The careful selection of patients with fewer risk factors for a GI perforation will allow for greater patient benefit from bevacizumab.

Acknowledgments We wish to thank our colleagues (at Japanese Red Cross Kumamoto Hospital; Saiseikai Kumamoto Hospital; Arai Municipal Hospital; National Hospital Organization Kumamoto Medical Center; Kumamoto City Hospital; Coloproctology Center, Takano Hospital; Health Insurance Hitoyoshi General Hospital; Minamata City General Hospital and Medical Center; Kumamoto Central Hospital; Yatsushiro Social Insurance General Hospital; Kumamoto Breast & Gastrointestinal Surgical Hospital; and Yamaga Medical Center) for their assistance with the collection and analysis of data.

Conflict of interest None of the authors has any conflict of interest.

References

1. Kotake K, Honjo S, Sugihara K et al (2003) Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. *Dis Colon Rectum* 46(10 Suppl):S32–S43
2. Muto T, Kotake K, Koyama Y (2001) Colorectal cancer statistics in Japan: data from JSCCR registration, 1974–1993. *Int J Clin Oncol* 6(4):171–176
3. Folkman J (1971) Tumor angiogenesis: therapeutic implications. *N Engl J Med* 285(21):1182–1186

4. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. *Semin Oncol* 29(6 Suppl 16):15–18
5. Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. *J Mol Med* 77(7):527–543
6. Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. *Nat Med* 10(2):145–147
7. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. *Nat Med* 7(9):987–989
8. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 350(23):2335–2342
9. Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol* 26(12):2013–2019
10. Doi T, Boku N, Kato K et al. (2010) Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. *Jpn J Clin Oncol* 40(10):913–920
11. Kabbinnavar F, Hurwitz H, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. *J Clin Oncol* 21(1):60–65
12. Tamiya A, Yamazaki K, Boku N et al (2009) Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. *Int J Clin Oncol* 14(6):513–517
13. Van Cutsem E, Rivera F, Berry S et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. *Ann Oncol* 20(11):1842–1847
14. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *N Engl J Med* 349(5):427–434
15. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. *J Clin Oncol* 25(12):1539–1544
16. Kabbinnavar FF, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. *J Clin Oncol* 23(16):3697–3705
17. Grothey A, Sugrue MM, Purdie DM et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). *J Clin Oncol* 26(33):5326–5334
18. Van Cutsem E, M Michael, S Berry (2007) Preliminary safety and efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI, and capecitabine for mCRC: first-BEAT trial. *Gastrointestinal Cancer Symposium* (abstract #346)
19. Flynn P, MM Sugrue, DM Purdie (2008) Serious bleeding events are uncommon in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: results from the BRiTE observational Cohort Study. *Gastrointestinal Cancer Symposium* (abstract #346)
20. Kozloff M, J Hainsworth, S Badarinarath (2007) Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer treated with bevacizumab (BV) plus chemotherapy. *Gastrointestinal Cancer Symposium* (abstract #364)
21. Sugrue MM, M Kozloff, J Hainsworth (2007) Safety and effectiveness of bevacizumab plus chemotherapy in elderly patients with mCRC: result from the BRiTE registry. *Gastrointestinal Cancer Symposium* (abstract #345)
22. Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. *Lancet Oncol* 10(6):559–568
23. Hedrick E, M Kozloff, J Hainsworth (2006) Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). *ASCO Annual Meeting* (abstract #3536), Atlanta, USA
24. Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. *Ann Surg Oncol* 14(6):1860–1869
25. Han ES, Monk BJ (2007) What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? *Gynecol Oncol* 105(1):3–6

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

GEST: Gemcitabine and S-1 Trial

Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda, Shinichi Ohkawa, Hiroaki Yanagimoto, Narikazu Boku, Akira Fukutomi, Kazuya Sugimori, Hideo Baba, Kenji Yamao, Tomotaka Shimamura, Masayuki Sho, Masayuki Kitano, Ann-Lii Cheng, Kazuhiro Mizumoto, Jen-Shi Chen, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Atsushi Sato, Yasuo Ohashi, Takuji Okusaka, and Masao Tanaka

See accompanying editorial doi: 10.1200/JCO.2013.48.7660

ABSTRACT

Purpose

The present phase III study was designed to investigate the noninferiority of S-1 alone and superiority of gemcitabine plus S-1 compared with gemcitabine alone with respect to overall survival.

Patients and Methods

The subjects were chemotherapy-naïve patients with locally advanced or metastatic pancreatic cancer. Patients were randomly assigned to receive only gemcitabine (1,000 mg/m² on days 1, 8, and 15 of a 28-day cycle), only S-1 (80, 100, or 120 mg/d according to body-surface area on days 1 through 28 of a 42-day cycle), or gemcitabine plus S-1 (gemcitabine 1,000 mg/m² on days 1 and 8 plus S-1 60, 80, or 100 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle).

Results

In the total of 834 enrolled patients, median overall survival was 8.8 months in the gemcitabine group, 9.7 months in the S-1 group, and 10.1 months in the gemcitabine plus S-1 group. The noninferiority of S-1 to gemcitabine was demonstrated (hazard ratio, 0.96; 97.5% CI, 0.78 to 1.18; $P < .001$ for noninferiority), whereas the superiority of gemcitabine plus S-1 was not (hazard ratio, 0.88; 97.5% CI, 0.71 to 1.08; $P = .15$). All treatments were generally well tolerated, although hematologic and GI toxicities were more severe in the gemcitabine plus S-1 group than in the gemcitabine group.

Conclusion

Monotherapy with S-1 demonstrated noninferiority to gemcitabine in overall survival with good tolerability and presents a convenient oral alternative for locally advanced and metastatic pancreatic cancer.

J Clin Oncol 30. © 2013 by American Society of Clinical Oncology

INTRODUCTION

Pancreatic cancer (PC) is currently the eighth leading cause of cancer-related mortality worldwide, with an estimated 266,000 deaths in 2008.¹ Gemcitabine became the standard treatment for advanced PC, improving overall survival (OS) compared with fluorouracil.² Although various gemcitabine-based combination regimens have been evaluated, only erlotinib added to gemcitabine showed a survival benefit over gemcitabine, and that was marginal.³

Fluorouracil/leucovorin plus irinotecan plus oxaliplatin (FOLFIRINOX), a gemcitabine-free combination regimen, has recently demonstrated a clear survival benefit compared with gemcitabine for patients with metastatic PC who have a performance status of 0 to 1.⁴ However, because FOLFIRINOX is associated with significant toxicity, this regimen must be limited to patients with good performance status and requires close monitoring.⁵

In Japan, clinical trials of S-1 (TS-1; Taiho Pharmaceutical, Tokyo, Japan) have been conducted since the early 2000s for patients with PC. S-1

Author affiliations appear at the end of this article.

Published online ahead of print at www.jco.org on Month XX, 2013.

Written on behalf of the GEST study Group.

Supported by Taiho Pharmaceutical and TTY Biopharm.

Presented in part at the 47th Annual Meeting of the American Society of Clinical Oncology, June 3-7, 2011, Chicago, IL (abstract 4007).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical trial information: NCT00498225.

Corresponding author: Takuji Okusaka, MD, Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; e-mail: tokusaka@ncc.go.jp.

© 2013 by American Society of Clinical Oncology

0732-183X/13/3022-1/\$20.00

DOI: 10.1200/JCO.2012.43.3680

is an oral fluoropyrimidine derivative shown to be effective for gastric and various other types of cancers.^{6,7} Phase II studies of S-1 as first-line therapy for metastatic PC resulted in good response rates of 21.1% to 37.5%.^{8,9} Consequently, S-1 was approved for the indication of PC in Japan in 2006. Development of gemcitabine plus S-1 (GS) studies have also been initiated, mainly in Japan, and two phase II studies reported high response rates of 44.4% to 48.5% and good median OS of 10.1 to 12.5 months.^{10,11}

Because S-1 and GS have shown promising activity in PC, the present randomized phase III study (GEST study) was designed to evaluate whether S-1 alone is noninferior to gemcitabine and whether GS is superior to gemcitabine alone for locally advanced and meta-static PC with respect to OS.

PATIENTS AND METHODS

Study Design

This randomized phase III study, sponsored by Taiho Pharmaceutical in Japan and TTY Biopharm in Taiwan, was conducted as a postmarketing study in Japan and as a registration study in Taiwan and was in compliance with the Declaration of Helsinki. Data were collected by a contract research organization contracted by the sponsors and were analyzed by a bio-statistician (Y.O.). An independent data and safety monitoring committee reviewed efficacy and safety data. The study was approved by the ethics committee or institutional review board of each participating center.

Patients

All patients provided written informed consent. Enrollment criteria were locally advanced or metastatic PC, histologically or cytologically proven diagnosis of adenocarcinoma or adenosquamous carcinoma, no prior chemotherapy or radiotherapy for PC, age of more than 20 years (the protocol was amended to restrict the eligible age to < 80 years after four of the first eight patients who were ≥ 80 years experienced serious adverse events), an Eastern Cooperative Oncology Group performance status score of 0 to 1, and adequate organ functions (see Appendix, online only).

Treatment

Random assignment was performed centrally with stratification by extent of disease (locally advanced disease v metastatic disease) and institution

using the minimization method. Patients allocated to gemcitabine alone received gemcitabine at a dose of 1,000 mg/m² intravenously over 30 minutes on days 1, 8, and 15 of a 28-day cycle. Patients allocated to S-1 alone received S-1 orally twice daily at a dose according to the body-surface area (BSA) (< 1.25 m², 80 mg/d; ≥ 1.25 to < 1.5 m², 100 mg/d; ≥ 1.5 m², 120 mg/d) on days 1 through 28 of a 42-day cycle. Patients allocated to GS received gemcitabine at a dose of 1,000 mg/m² on days 1 and 8 plus S-1 orally twice daily at a dose according to the BSA (< 1.25 m², 60 mg/d; ≥ 1.25 to < 1.5 m², 80 mg/d; ≥ 1.5 m², 100 mg/d) on days 1 through 14 of a 21-day cycle. The dose levels of S-1 used in the GS group were based on the results of a previous phase II study of GS, in which 1,000 mg/m² of gemcitabine was combined with 120 mg/d, 100 mg/d, and 80 mg/d of S-1. In that study, the rate of treatment withdrawal due to adverse events was 41% (22 of 54 patients), the rate of grade 3 or worse neutropenia was 80%, and the dose was reduced in 56% of the patients (30 of 54 patients).¹¹ Consequently, 20 mg/d lower doses of S-1 than those used in the S-1 monotherapy group were used in the GS group in the present study.

In the event of predefined toxic events, protocol-specified treatment modifications were permitted (see Appendix).

Assessments

Physical examinations, CBCs, and biochemistry tests were usually checked at 2-week intervals in the S-1 group and at each time of administration of gemcitabine both in the gemcitabine group and in the GS group. All adverse events were assessed according to the Common Terminology Criteria for Adverse Events, version 3.0. Computed tomography or magnetic resonance imaging was performed every 6 weeks until disease progression, and response was assessed by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0.¹² Quality of life was assessed using the EQ-5D questionnaire¹³ at baseline and 6, 12, 24, 48, and 72 weeks after the start of treatment. In the event of predefined toxic events, protocol-specified treatment modifications were permitted (see Appendix).

Statistical Analysis

The primary end point was OS, defined as time from date of random assignment to date of death from any cause. Secondary end points were progression-free survival (PFS), objective response rate, safety, and quality of life. PFS was counted from the date of random assignment to the date of death without progression or of progression as confirmed by the investigator's assessment. The median OS was assumed to be 7.5 months in the gemcitabine group, 8.0 months in the S-1 group, and 10.5 months in the GS group. To maintain a one-sided significance level of .025 for the entire study while testing two hypotheses (ie, noninferiority and superiority), the one-sided significance

EQ-5D: EuroQol 5 Dimension




Fig 1. CONSORT diagram. GS, gemcitabine plus S-1.

GS or S-1 v Gemcitabine for Pancreatic Cancer

level for each comparison was set at .0125. The statistical considerations are detailed in the Appendix.

The superiority of GS was evaluated by the stratified log-rank test. To assess the noninferiority of S-1, we used the Cox proportional hazards model to calculate two-sided, 97.5% CIs of the hazard ratio (HR). The noninferiority margin of S-1 was set at 1.33; that is, the null hypothesis was that the median OS with S-1 would be approximately 2 months shorter than with gemcitabine. We decided this setting was justified considering the convenience of S-1 and the because there are few effective drugs for the disease. Furthermore, to interpret the obtained data, the Bayesian analysis of the log HR on the basis of the noninformative prior distribution was preplanned. Posterior probability with log HR within a stricter threshold (log 1.15) was also calculated.¹⁴

In each assigned group, the time-to-event distribution was estimated with the Kaplan-Meier method. The 95% CI of the median survival time was calculated by the method of Brookmeyer and Crowley.¹⁵ In addition, the Greenwood formula¹⁶ was used to calculate the 95% CI for survival rates. In subgroup analyses, interaction tests were performed to assess the homogeneity of the effect of treatment on OS.

The primary end point was analyzed for the full analysis set. All *P* value evaluations were two-tailed. Data analyses were done with SAS, version 9.1.3 (SAS Institute, Cary, NC).

RESULTS

Patients

Between July 2007 and October 2009, a total of 834 patients were enrolled from 75 institutions in Japan and Taiwan (768 in Japan and 66 in Taiwan). Two patients in the GS group were excluded from the study because enrollment was conducted before obtaining written informed consent. The remaining 832 patients were included in the full analysis set and used to calculate OS and PFS (Fig 1). The three treatment groups were well balanced with respect to demographic and baseline characteristics (Table 1).

F1, AQ:D
T1

Study Treatment

The median duration of treatment was 2.6 months in the gemcitabine group, 2.6 months in the S-1 group, and 4.3 months in the GS group. The main reasons for treatment discontinuation were either disease progression (202 patients [72.9%] in the gemcitabine group,

Table 1. Demographics and Baseline Characteristics of Patients (full-analysis set population)

Characteristic	Gemcitabine (n = 277)		S-1 (n = 280)		GS (n = 275)		Total (N = 832)	
	No.	%	No.	%	No.	%	No.	%
Sex								
Male	170	61.4	170	60.7	158	57.5	498	59.9
Female	107	38.6	110	39.3	117	42.5	334	40.1
Age, years								
< 65	134	48.4	145	51.8	137	49.8	416	50.0
≥ 65	143	51.6	135	48.2	138	50.2	416	50.0
ECOG PS								
0	181	65.3	178	63.6	172	62.5	531	63.8
1	96	34.7	102	36.4	103	37.5	301	36.2
Extent of disease								
Locally advanced	66	23.8	68	24.3	68	24.7	202	24.3
Metastatic	211	76.2	212	75.7	207	75.3	630	75.7
Type of tumor								
Adenocarcinoma	272	98.2	276	98.6	272	98.9	820	98.6
Adenosquamous carcinoma	5	1.8	4	1.4	3	1.1	12	1.4
Pancreas excision								
No	254	91.7	264	94.3	248	90.2	766	92.1
Yes	23	8.3	16	5.7	27	9.8	66	7.9
Tumor location*								
Head	122	44.0	110	39.3	116	42.2	348	41.8
Body	88	31.8	124	44.3	102	37.1	314	37.7
Tail	68	24.5	55	19.6	66	24.0	189	22.7
Biliary drainage								
No	202	72.9	217	77.5	209	76.0	628	75.5
Yes	75	27.1	63	22.5	66	24.0	204	24.5
CEA, ng/mL								
Median	5.7		5.6		5.9		5.7	
IQR	3.0-20.1		2.5-18.4		2.5-20.7		2.6-19.5	
CA19-9, U/mL								
Median	1,044		726		441		712	
IQR	52-5,002		64-5,000		45-5,090		55-5,002	
CRP, mg/dL								
Median	0.40		0.50		0.40		0.43	
IQR	0.11-1.38		0.18-1.57		0.15-1.60		0.15-1.57	

Abbreviations: CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; GS, gemcitabine plus S-1; IQR, interquartile range.
*Including patients with tumors involving multiple sites.

215 [76.8%] in the S-1 group, and 162 [58.9%] in the GS group) or adverse events (40 patients [14.4%] in the gemcitabine group, 38 [13.6%] in the S-1 group, and 76 [27.6%] in the GS group). The median relative dose-intensity was 83.0% in the gemcitabine group, 96.1% in the S-1 group, and 83.3% for gemcitabine and 87.4% for S-1 in the GS group.

Survival

The median duration of follow-up for surviving patients was 18.4 months (range, 0.3 to 36.9 months) as of July 31, 2010. The analysis of OS was based on 710 deaths (85.3%) among the 832 patients. The median OS was 8.8 months (95% CI, 8.0 to 9.7) in the gemcitabine group, 9.7 months (95% CI, 7.6 to 10.8) in the S-1 group, and 10.1 months (95% CI, 9.0 to 11.2) in the GS group (Fig 2A). OS rates at 12 and 24 months were respectively 35.4% and 9.2% in the gemcitabine group, 38.7% and 12.7% in the S-1 group, and 40.7% and 14.5% in the GS group. The noninferiority of S-1 to gemcitabine with respect to OS was demonstrated (HR, 0.96; 97.5% CI, 0.78 to 1.18; $P < .001$ for

noninferiority). The Bayesian posterior probability that the HR of S-1 relative to gemcitabine would be less than 1.15 was calculated to be 98% on the basis of the noninformative prior distribution. However, GS failed to improve OS at a statistically significant level as compared with gemcitabine (HR, 0.88; 97.5% CI, 0.71 to 1.08; $P = .15$).

The analysis of PFS was based on 793 events (95.3%) among the 832 patients. The median PFS was 4.1 months (95% CI, 3.0 to 4.4) in the gemcitabine group, 3.8 months (95% CI, 2.9 to 4.2) in the S-1 group, and 5.7 months (95% CI, 5.4 to 6.7) in the GS group (Fig 2B). PFS rates at 6 and 12 months were respectively 29.8% and 9.1% in the gemcitabine group, 26.9% and 7.2% in the S-1 group, and 47.9% and 20.3% in the GS group. S-1 was shown to be noninferior to gemcitabine with respect to PFS (HR, 1.09; 97.5% CI, 0.90 to 1.33; $P = .02$ for noninferiority), and GS significantly improved PFS compared with gemcitabine (HR, 0.66; 97.5% CI, 0.54 to 0.81; $P < .001$).

Subgroup analyses of survival according to pretreatment characteristics showed no significant interaction between S-1 and gemcitabine in any subgroup (Fig 3A). However, GS showed a favorable HR compared with gemcitabine in the subsets of patients with locally advanced disease or patients with a performance status of 1 (Fig 3B).

Response to Therapy

The objective response rate was 13.3% (95% CI, 9.3 to 18.2) in the gemcitabine group, 21.0% (95% CI, 16.1 to 26.6) in the S-1 group, and 29.3% (95% CI, 23.7 to 35.5) in the GS group (Table 2). The objective response rate was significantly higher in the S-1 group ($P = .02$) and in the GS group ($P < .001$) than in the gemcitabine group.

Second-Line Chemotherapy

Second-line chemotherapy was performed in 184 patients (66.4%) in the gemcitabine group, 185 (66.1%) in the S-1 group, and 172 (62.5%) in the GS group. In the gemcitabine group, 140 patients (50.5%) received S-1 alone or S-1-based regimens, and in the S-1 group 162 (57.9%) received gemcitabine alone or gemcitabine-based regimens as second-line chemotherapy. The most common second-line regimens in the GS group were gemcitabine alone (61 patients), GS (53 patients), S-1 alone (24 patients), irinotecan (six patients), and fluorouracil/leucovorin plus oxaliplatin (four patients). In Japan and Taiwan, the use of treatments such as erlotinib, oxaliplatin, and irinotecan for PC was not approved at the time of this study; hence gemcitabine, S-1, or both were used in most patients as second-line chemotherapy.

Adverse Events and Quality-Adjusted Life Years

The major grade 3 or worse adverse events are listed in Table 3. Patients in the gemcitabine group had significantly higher incidences of grade 3 or worse leukopenia, neutropenia, thrombocytopenia, elevated AST levels, and elevated ALT levels as compared with patients in the S-1 group. However, the incidence of grade 3 or worse diarrhea was higher in the S-1 group than in the gemcitabine group. Patients in the GS group had significantly higher incidences of grade 3 or worse leukopenia, neutropenia, thrombocytopenia, rash, diarrhea, and stomatitis than patients in the gemcitabine group.

There were three deaths considered possibly related to the protocol treatment (interstitial lung disease, sepsis, and acute hepatitis B) in the gemcitabine group, one in the S-1 group (unknown cause), and




Fig 2. Kaplan-Meier estimates of (A) overall survival and (B) progression-free survival according to treatment group. GS, gemcitabine plus S-1.

GS or S-1 v Gemcitabine for Pancreatic Cancer




Fig 3. Forest plots of treatment effects on overall survival in subgroup analyses. Forest plots show effects on overall survival of patients in each subgroup. (A) S-1; (B) gemcitabine plus S-1 (GS). Each black circle shows the treatment response, ECOG PS, Eastern Cooperative Oncology Group performance status.

four in the GS group (unknown cause associated with myelosuppression, cerebral infarction, cerebrovascular disorder, and interstitial lung disease). The results of quality-adjusted life years (QALYs) are in the Appendix and the details of quality-of-life assessments will be reported elsewhere.

DISCUSSION

The overall and PFS curves in the S-1 group were nearly identical to those in the gemcitabine group, confirming the noninferiority of S-1

to gemcitabine in terms of OS and PFS (Fig 2A, 2B). Toxicity profiles of these two drugs differed slightly: gemcitabine tended to show hematologic toxicity, whereas S-1 tended to show GI toxicity. However, both S-1 and gemcitabine were generally well tolerated. Furthermore, the results of QALY evaluation demonstrated that S-1 and gemcitabine were equivalent. Hence our results suggest that S-1 can be used as first-line therapy as a convenient oral alternative for locally advanced and metastatic PC. To the best of our knowledge, this is the first phase III study to demonstrate the noninferiority of a single anticancer agent to gemcitabine alone for locally advanced and metastatic PC.

Table 2. Objective Response Rates (patients with measurable lesions)

Variable	Gemcitabine (n = 241)		S-1 (n = 248)		GS (n = 242)		P	
	No.	%	No.	%	No.	%	Gemcitabine v S-1	Gemcitabine v GS
Response								
Complete response	1	0.4	0	0	2	0.8		
Partial response	31	12.9	52	21.0	69	28.5		
Stable disease	119	49.4	105	42.3	102	42.1		
Progressive disease	75	31.1	69	27.8	37	15.3		
Objective response rate*	32	13.3	52	21.0	71	29.3	.02	< .001
95% CI	9.3 to 18.2		16.1 to 26.6		23.7 to 35.5			
Disease control rate†	151	62.7	157	63.3	173	71.5	.88	.04
95% CI	56.2 to 68.8		57.0 to 69.3					

Abbreviation: GS, gemcitabine plus S-1.

*The objective response rate was defined as the proportion of patients who had a complete response or partial response.

†The disease control rate was defined as the proportion of patients who had a complete response, partial response, or stable disease.

At the time of planning this study, the subjects of nearly all phase III trials included both patients with locally advanced as well as those with metastatic PC. However, because locally advanced and metastatic diseases are two clinical entities, it is recently recommended that patients with locally advanced disease should be studied separately from those with metastatic disease.¹⁷ Although this study included locally advanced disease, subgroup analysis of extent of disease showed no significant interaction between S-1 and gemcitabine (Fig 3A). Moreover, the OS curve in the S-1 group was still similar to those in the gemcitabine group in both locally advanced and metastatic disease (Fig 4A, 4B). Regarding pathologic diagnosis, our study included adenosquamous carcinoma, although its percentage was very low (1.4% of whole population). When the data were reanalyzed after

excluding patients with adenosquamous carcinoma, the results for OS for gemcitabine versus S-1 was unchanged (HR, 0.96; 95% CI, 0.81 to 1.15). The selection of one treatment over the other will depend primarily on patient preference, clinical factors, or drug costs, as biomarkers indicating effective use of S-1 or gemcitabine do not exist at this time.

Regarding GS, the OS did not differ significantly from gemcitabine, although the PFS was significantly longer in the GS group. Second-line chemotherapy mainly with S-1 in the gemcitabine group may be one reason for this discrepancy. The median OS in the gemcitabine group was 8.8 months, which is longer than those previously reported for gemcitabine in other phase III studies for locally advanced and metastatic PC.^{2,3,18-24} Although the efficacy of second-line

Table 3. Grade 3 or Higher Adverse Events (Safety Population)

Event	Gemcitabine (n = 273)		S-1 (n = 272)		GS (n = 267)		P (Fisher's exact test)	
	No.	%	No.	%	No.	%	Gemcitabine v S-1	Gemcitabine v GS
Hematologic								
Leukocytes	51	18.7	10	3.7	101	37.8	< .001	< .001
Neutrophils	112	41.0	24	8.8	166	62.2	< .001	< .001
Platelets	30	11.0	4	1.5	46	17.2	< .001	.05
Hemoglobin	39	14.3	26	9.6	46	17.2	.11	.41
Nonhematologic								
ALT	41	15.0	16	5.9	29	10.9	< .001	.16
AST	41	15.0	21	7.7	32	12.0	.01	.32
Bilirubin	26	9.5	39	14.3	23	8.6	.09	.77
Fatigue	10	3.7	18	6.6	13	4.9	.13	.53
Rash	2	0.7	2	0.7	11	4.1	1.00	.01
Anorexia	20	7.3	31	11.4	25	9.4	.11	.44
Diarrhea	3	1.1	15	5.5	12	4.5	.004	.02
Mucositis/stomatitis	0	0.0	2	0.7	6	2.2	.25	.01
Nausea	5	1.8	5	1.8	12	4.5	1.00	.09
Vomiting	2	0.7	4	1.5	12	4.5	.45	.006
Febrile neutropenia	1	0.4	1	0.4	5	1.9	1.00	.12
Infection with normal ANC	6	2.2	7	2.6	6	2.2	.79	1.00
Pneumonitis	5	1.8	0	0.0	2	0.7	.06	.45

Note. Grades of adverse events were defined according to the Common Terminology Criteria for Adverse Events (version 3.0).

Abbreviations: ANC, absolute neutrophil count; GS, gemcitabine plus S-1.

GS or S-1 v Gemcitabine for Pancreatic Cancer




Fig 4. Kaplan-Meier estimates of overall survival in (A) locally advanced disease and (B) metastatic disease. GS, gemcitabine plus S-1.

therapy was not analyzed in this study, a phase II study of second-line S-1 in patients with gemcitabine-refractory PC showed a 15% response rate and 58% disease control rate.²⁵ Compared with the GS group, which had no promising second-line therapy, the use of S-1 as second-line therapy in the gemcitabine group might have contributed to prolonged survival.

The lack of a significant difference in OS between gemcitabine and GS suggests that gemcitabine and S-1 could be used sequentially rather than concurrently. However, the GS group showed a high response rate and favorable PFS, with a better HR of 0.66 compared with other gemcitabine-based combination regimens in other phase III studies (HR = 0.75 to 1.07).^{3,18,20,22,24} Furthermore, the GS group showed a favorable HR for OS in patients with locally advanced disease or patients with a performance status of 1 in the subgroup analyses. Therefore, it is speculated that there may be room to select GS therapy, depending on the profile of the patients and further investigations.

Regarding oral fluoropyrimidines other than S-1, capecitabine has been studied in patients with PC, mainly in the West. In two phase

III studies, a combination of gemcitabine plus capecitabine did not significantly prolong survival as compared with gemcitabine alone.^{19,20} The results of a meta-analysis of these phase III studies, however, demonstrated that survival was significantly prolonged by combined treatment, with an HR of 0.86,²⁰ which is similar to the HR for GS in the present study (0.88).

One limitation of our study is that it is uncertain whether our results can be simply extrapolated to Western patients because pharmacokinetics and pharmacodynamics of S-1 between Westerners and East Asians may be different.^{26,27} Although S-1 is available for PC only in Japan at the moment, if S-1 is used in Western patients, its effectiveness should be monitored and the dose should be carefully adjusted accordingly. Another potential limitation is that the protocol-specified noninferiority margin of 1.33 may be large. However, the result of point estimate of the HR of S-1 was 0.96 and actual upper limit of the 97.5% CI was 1.18, which was sufficiently lower than the prespecified margin of 1.33. Furthermore, Bayesian posterior probability with log HR within a stricter threshold (log 1.15) was 98%.

Given that most gemcitabine-based combination regimens have not been shown to be significantly superior to gemcitabine alone and that FOLFIRINOX has demonstrated overwhelming superiority to gemcitabine in a phase III study, reporting an HR of 0.57,⁴ the development of gemcitabine-free combination regimens for first-line treatment seems to be warranted. However, because FOLFIRINOX requires the placement of a central venous access port for continuous intravenous infusion of fluorouracil, it can be expected that S-1, an oral fluoropyrimidine, will replace the continuous infusion of fluorouracil in the future.

In conclusion, this study has verified the noninferiority of S-1 to gemcitabine, thereby suggesting that S-1 can be used as first-line therapy for locally advanced and metastatic PC. Because S-1 was confirmed to be a key treatment for PC, S-1-based regimens are expected to be developed in the future to improve the management of this formidable disease.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

AQ: E

Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: None **Consultant or Advisory Role:** Hideki Ueno, Taiho Pharmaceutical (C); Tatsuya Ioka, Taiho Pharmaceutical (U); Shinichi Ohkawa, Taiho Pharmaceutical (C); Narikazu Boku, Taiho Pharmaceutical (U); Kenji Yamao, Taiho Pharmaceutical (C); Ann-Lii Cheng, Boehringer Ingelheim (C), sanofi-aventis (C), TTY Biopharm (C); Kazuhiro Mizumoto, Taiho Pharmaceutical (C); Jen-Shi Chen, TTY Biopharm (C); Junji Furuse, Bayer (C), GlaxoSmithKline (C), Kowa (C), Novartis (C), Taiho Pharmaceutical (C); Akihiro Funakoshi, Taiho Pharmaceutical (C); Takashi Hatori, Taiho Pharmaceutical (C); Taketo Yamaguchi, Taiho Pharmaceutical (C); Atsushi Sato, Taiho Pharmaceutical (C); Yasuo Ohashi, Taiho Pharmaceutical (C); Takuji Okusaka, Taiho Pharmaceutical (C); Masao Tanaka, Taiho Pharmaceutical (C) **Stock**

Ownership: None **Honoraria:** Hideki Ueno, Taiho Pharmaceutical, Eli Lilly; Tatsuya Ioka, Taiho Pharmaceutical; Masafumi Ikeda, Taiho Pharmaceutical; Shinichi Ohkawa, Taiho Pharmaceutical, Eli Lilly, Chugai; Hiroaki Yanagimoto, Taiho Pharmaceutical; Narikazu Boku, Taiho Pharmaceutical; Akira Fukutomi, Taiho Pharmaceutical, Eli Lilly; Kazuya Sugimori, Taiho Pharmaceutical; Hideo Baba, Taiho Pharmaceutical; Kenji Yamao, Taiho Pharmaceutical, Eli Lilly; Masayuki Sho, Taiho Pharmaceutical; Jen-Shi Chen, TTY Biopharm; Junji Furuse, Taiho Pharmaceutical, Bayer, Eli Lilly; Akihiro Funakoshi, Taiho Pharmaceutical; Atsushi Sato, Taiho Pharmaceutical; Yasuo Ohashi, Taiho Pharmaceutical; Takuji Okusaka, Taiho Pharmaceutical, Eli Lilly; Masao Tanaka, Taiho Pharmaceutical **Research Funding:** Hideki Ueno, Taiho Pharmaceutical; Tatsuya Ioka, Taiho Pharmaceutical; Masafumi Ikeda, Taiho Pharmaceutical; Shinichi Ohkawa, Taiho Pharmaceutical, Eli Lilly, Chugai, Oncotherapy Science, Yakult, Abbott, Amgen; Hiroaki Yanagimoto, Taiho Pharmaceutical; Narikazu Boku, Taiho Pharmaceutical Co. Ltd; Akira Fukutomi, Taiho Pharmaceutical, Eli Lilly; Kazuya Sugimori, Taiho Pharmaceutical; Hideo Baba, Taiho Pharmaceutical; Kenji Yamao, Taiho Pharmaceutical; Tomotaka Shimamura, Taiho Pharmaceutical; Masayuki Sho, Taiho Pharmaceutical; Ann-Lii Cheng, TTY Biopharm; Kazuhiro Mizumoto, Taiho Pharmaceutical; Jen-Shi Chen, TTY Biopharm; Junji Furuse, Taiho Pharmaceutical, Bayer, Pfizer, Yakult; Akihiro Funakoshi, Taiho Pharmaceutical; Takashi Hatori, Taiho Pharmaceutical; Taketo Yamaguchi, Taiho Pharmaceutical; Yasuo Ohashi, Taiho Pharmaceutical;

Takuji Okusaka, Taiho Pharmaceutical, Eli Lilly; Masao Tanaka, Taiho Pharmaceutical **Expert Testimony:** None **Other Remuneration:** None

Eli Lilly

AUTHOR CONTRIBUTIONS

AQ: F

Conception and design: Hideki Ueno, Tatsuya Ioka, Shinichi Ohkawa, Narikazu Boku, Kenji Yamao, Kazuhiro Mizumoto, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Atsushi Sato, Yasuo Ohashi, Takuji Okusaka, Masao Tanaka

Provision of study materials or patients: Masayuki Kitano, Masao Tanaka

Collection and assembly of data: Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda, Shinichi Ohkawa, Hiroaki Yanagimoto, Narikazu Boku, Akira Fukutomi, Kazuya Sugimori, Hideo Baba, Kenji Yamao, Tomotaka Shimamura, Masayuki Sho, Masayuki Kitano, Ann-Lii Cheng, Kazuhiro Mizumoto, Jen-Shi Chen, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Takuji Okusaka, Masao Tanaka

Data analysis and interpretation: Hideki Ueno, Tatsuya Ioka, Shinichi Ohkawa, Narikazu Boku, Kenji Yamao, Kazuhiro Mizumoto, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Atsushi Sato, Yasuo Ohashi, Takuji Okusaka, Masao Tanaka

Manuscript writing: All authors

Final approval of manuscript: All authors

REFERENCES

- Jemal A, Bray F, Center MM, et al: Global cancer statistics. *CA Cancer J Clin* 61:69-90, 2011
- Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. *J Clin Oncol* 15:2403-2413, 1997
- Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 25:1960-1966, 2007
- Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 364:1817-1825, 2011
- Saif MW, Chabot J: Chemotherapy: Metastatic pancreatic cancer—Is FOLFIRINOX the new standard? *Nat Rev Clin Oncol* 8:452-453, 2011
- Saif MW, Syrigos KN, Katirtzoglou NA: S-1: A promising new oral fluoropyrimidine derivative. *Expert Opin Investig Drugs* 18:335-348, 2009
- Shirasaka T: Development history and concept of an oral anticancer agent S-1 (TS-1): Its clinical usefulness and future vistas. *Jpn J Clin Oncol* 39:2-15, 2009
- Ueno H, Okusaka T, Ikeda M, et al: An early phase II study of S-1 in patients with metastatic pancreatic cancer. *Oncology* 68:171-178, 2005
- Okusaka T, Funakoshi A, Furuse J, et al: A late phase II study of S-1 for metastatic pancreatic cancer. *Cancer Chemother Pharmacol* 61:615-621, 2008
- Nakamura K, Yamaguchi T, Ishihara T, et al: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. *Br J Cancer* 94:1575-1579, 2006
- Ueno H, Okusaka T, Furuse J, et al: Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. *Jpn J Clin Oncol* 41:953-958, 2011
- Therasse P, Arbuuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 92:205-216, 2000
- EuroQol: A new facility for the measurement of health-related quality of life—The EuroQol Group. *Health Policy* 16:199-208, 1990
- Spiegelhalter DJ, Freedman LS, Parmar MKB: Bayesian approaches to randomized trials. *J R Stat Soc* 157:357-387, 1994
- Brookmeyer R, Crowley J: A confidence interval for the median survival time. *Biometrics* 38:29-41, 1982
- Kalbfleisch JD, Prentice RL: *The Statistical Analysis of Failure Time Data*. New York, NY, Wiley, 1980, p. 14
- Philip PA, Mooney M, Jaffe D, et al: Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. *J Clin Oncol* 27:5660-5669, 2009
- Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. *J Clin Oncol* 24:3946-3952, 2006
- Herrmann R, Bodoky G, Rihstaller T, et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Res and the Central European Cooperative Oncology Group. *J Clin Oncol* 25:2212-2217, 2007
- Cunningham D, Chau I, Stocken DD, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. *J Clin Oncol* 27:5513-5518, 2009
- Poplin E, Feng Y, Berlin J, et al: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group. *J Clin Oncol* 27:3778-3785, 2009
- Philip PA, Benedetti J, Corless CL, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. *J Clin Oncol* 28:3605-3610, 2010
- Kindler HL, Niedzwiecki D, Hollis D, et al: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). *J Clin Oncol* 28:3617-3622, 2010
- Kindler HL, Ioka T, Richel DJ, et al: Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomised phase 3 study. *Lancet Oncol* 12:256-262, 2011
- Morizane C, Okusaka T, Furuse J, et al: A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. *Cancer Chemother Pharmacol* 63:313-319, 2009
- Haller DG, Cassidy J, Clarke SJ, et al: Potential regional differences for the tolerability profiles of fluoropyrimidines. *J Clin Oncol* 26:2118-2123, 2008
- Chuah B, Goh BC, Lee SC, et al: Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. *Cancer Sci* 102:478-483, 2011

Affiliations

Hideki Ueno and Takuji Okusaka, National Cancer Center Hospital; Junji Furuse, Kyorin University School of Medicine; Takashi Hatori, Tokyo Women's Medical University; Atsushi Sato, Showa University Hospital; Yasuo Ohashi, The University of Tokyo, Tokyo; Tatsuya Ioka, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka; Masafumi Ikeda, National Cancer Center Hospital East, Kashiwa; Shinichi

GS or S-1 v Gemcitabine for Pancreatic Cancer

Ohkawa, Kanagawa Cancer Center, Yokohama; Hiroaki Yanagimoto, Kansai Medical University Hirakata Hospital, Hirakata; Narikazu Boku and Akira Fukutomi, Shizuoka Cancer Center, Sunto-gun; Kazuya Sugimori, Yokohama City University Medical Center, Yokohama; Hideo Baba, Kumamoto University, Kumamoto; Kenji Yamao, Aichi Cancer Center Hospital, Nagoya; Tomotaka Shimamura, Saitama Cancer Center, Saitama; Masayuki Sho, Nara Medical University, Kashihara; Masayuki Kitano, Kinki University School of Medicine, Osakasayama; Kazuhiro Mizumoto and Masao Tanaka, Kyushu University; Akihiro Funakoshi, Fukuoka Sanno Hospital, Fukuoka; Taketo Yamaguchi, Chiba Cancer Center, Chiba; Shinichi Egawa, Tohoku University Graduate School of Medicine, Sendai, Japan; Ann-Lii Cheng, National Taiwan University Hospital, Taipei; and Jen-Shi Chen, Linkou Chang Gung Memorial Hospital and Chang Gung University, Tao-Yuan, Taiwan.



Unauthorized Use
Prohibited

AQ: G

Acknowledgment

We thank all the patients, their families, the investigators and medical staff and Yuji Sato and his clinical study team, Taiho Pharmaceutical, and TTY Biopharm for their participation in the study. We also thank J. Patrick Barron of the International Medical Communications Center of Tokyo Medical University, a remunerated consultant of Taiho Pharmaceutical, for his review of this article.

Appendix

Members of the Gemcitabine and S-1 Trial (GEST) Group

Steering committee. T. Okusaka, S. Egawa, J. Furuse, T. Yamaguchi, H. Ueno, T. Hatori, S. Ohkawa, N. Boku, K. Yamao, T. Ioka, A. Funakoshi, K. Mizumoto, M. Tanaka.

Independent data and safety monitoring committee. A. Nakao, I. Hyodo, S. Morita; Medical Advisor: A. Sato; Statistical Analyst: Y. Ohashi.

Principal investigators. National Cancer Center Hospital: T. Okusaka; Osaka Medical Center for Cancer and Cardiovascular Diseases: T. Ioka; National Cancer Center Hospital East: M. Ikeda, K. Nakachi; Kanagawa Cancer Center: S. Ohkawa; Kansai Medical University Hirakata Hospital: H. Yanagimoto; Yokohama City University Medical Center: K. Sugimori; Shizuoka Cancer Center: A. Fukutomi; Kumamoto University: H. Baba; Saitama Cancer Center: T. Shimamura, H. Hara; Aichi Cancer Center Hospital: K. Yamao; Nara Medical University: M. Sho; Kinki University School of Medicine, Department of Gastroenterology and Hepatology: M. Kitano; Sapporo-Kosei general Hospital: H. Miyagawa; Kyushu University, First Department of Surgery: K. Mizumoto; Jichi Medical University Hospital: H. Fujii; National Hospital Organization Osaka National Hospital: S. Nakamori; Kinki University School of Medicine, Department of Medical Oncology: T. Satoh, S. Ueda; Tochigi Cancer Center: Y. Hamamoto, E. Warita; Kyushu University, Department of Hepatology and Pancreatology: T. Ito; Teine-Keijinkai Hospital: H. Maguchi; Kyorin University School of Medicine: J. Furuse; Kyoto University Hospital: S. Matsumoto; Saitama Medical University International Medical Center: Y. Sasaki; Hokkaido University Hospital: Y. Komatsu; Tokyo Women's Medical University: M. Yamamoto; Saku Central Hospital: T. Hisa; Osaka City Juso Hospital: T. Yamazaki, O. Kurai; Kochi Health Sciences Center: A. Tsuji; National Kyushu Cancer Center: A. Funakoshi, M. Furukawa; Niigata Cancer Center Hospital: Y. Tsuchiya; Chiba Cancer Center: T. Yamaguchi; Osaka Red Cross Hospital: Y. Okabe; Tohoku University Graduate School of Medicine, Division of Gastroenterology: K. Sato; Tohoku University Graduate School of Medicine, Division of Gastroenterological Surgery: F. Motoi; Matsusaka Chuo General Hospital: H. Naota; Kyoto Second Red Cross Hospital: K. Yasuda; Hyogo College of Medicine: J. Fujimoto; Toyama University Hospital: A. Hosokawa; Fukuoka University Chikushi Hospital: T. Ueki; Hokkaido Social Insurance Hospital: K. Furuya; Kameda Medical Center: Y. Oyama; Nagoya Medical Center: H. Iwase; Shinshu University Hospital: N. Arakura; Yodogawa Christian Hospital: A. Watanabe; Osaka Medical College Hospital: H. Takiuchi; Kitano Hospital: S. Yazumi; Sakai Municipal Hospital: H. Ohzato; Kawasaki Medical School Hospital: K. Yoshida; Onomichi General Hospital: K. Hanada; Kagawa University Hospital: F. Goda; Shikoku Cancer Center: H. Iguchi; Keio University Hospital: T. Hibi; Osaka City General Hospital: H. Nebiki; Chiba University Hospital: T. Ishihara; Nippon Medical School Hospital: E. Uchida; Tokai University Hospital: T. Imaizumi; Nagoya City University Hospital: H. Ohara; Aichi Cancer Center Aichi Hospital: H. Kojima; Osaka City University Hospital: N. Yamada; Wakayama Medical University Hospital: H. Yamaue; Tokyo Medical University Hospital: F. Moriyasu; Showa University Northern Yokohama Hospital: K. Shimada; Shizuoka General Hospital: K. Matsumura; Hyogo Cancer Center: H. Nishisaki; Kanazawa University Hospital: S. Yano; Hiroshima Prefectural Hospital: K. Shinozaki; University of Miyazaki Hospital: H. Inatsu; Linkou Chang Gung Memorial Hospital and Chang Gung University: Jen-Shi Chen; National Taiwan University Hospital: Chiun Hsu; Taipei Veterans General Hospital: Jin-Hwang Liu; Chang Gung Medical Foundation, Kaohsiung: Kun-Ming Rau; Chung-Ho Memorial Hospital, Kaohsiung Medical University: Sheng-Fung Lin; China Medical University Hospital: Chang-Fang Chiu; Mackay Memorial Hospital, Taipei: Ruey-Kuen Hsieh; Changhua Christian Hospital: Cheng-Shyong Chang; Chi Mei Medical Center, Yong Kang: Wei-Shou Huang; Chi Mei Medical Center, Liou Ying: Wen-Tsun Huang; National Cheng Kung University Hospital: Wu-Chou Su.

Details of Adequate Organ Functions in Enrollment Criteria and Main Exclusion Criteria

Adequate organ functions were defined as follows: leukocyte count $\geq 3,500/\mu\text{L}$, neutrophil count $\geq 2,000/\mu\text{L}$, platelet count $\geq 100,000/\mu\text{L}$, hemoglobin level $\geq 9.0\text{ g/dL}$, serum creatinine level $\leq 1.2\text{ mg/dL}$, creatinine clearance $\geq 50\text{ mL/min}$, serum AST and ALT levels $\leq 150\text{ U/L}$, and serum total bilirubin level $\leq 2.0\text{ mg/dL}$ or $\leq 3.0\text{ mg/dL}$ if biliary drainage was performed.

Main exclusion criteria were as follows: pulmonary fibrosis or interstitial pneumonia; watery diarrhea; active infection; marked pleural effusion or ascites; and serious complications such as heart failure, peptic ulcer bleeding, or poorly controlled diabetes. Pancreatic cancers other than adenocarcinoma or adenosquamous carcinoma (eg, anaplastic carcinoma) were excluded from the study.

Dosage Adjustment Guideline for Toxicities

All treatment cycles were repeated until disease progression, unacceptable toxicity, or patient refusal. If patients had a leukocyte count of less than $2,000/\mu\text{L}$, a neutrophil count of less than $1,000/\mu\text{L}$, a platelet count of less than $70 \times 10^3/\mu\text{L}$, or grade 3 or worse rash, the administration of anticancer agents was postponed. S-1 was temporarily halted both in S-1 and in GS groups if patients had a creatinine level of 1.5 mg/dL or higher or grade 2 or worse diarrhea or stomatitis. Treatment was discontinued if these events did not resolve within

GS or S-1 v Gemcitabine for Pancreatic Cancer

4 weeks after treatment suspension. In patients who experienced febrile neutropenia, grade 4 leukopenia, neutropenia, or thrombocytopenia or grade 3 or worse rash, the dose of gemcitabine was reduced by 200 mg/m². In patients with febrile neutropenia; grade 4 leukopenia, neutropenia, or thrombocytopenia; a creatinine level of 1.5 mg/dL or higher; or grade 3 or worse diarrhea, stomatitis, or rash, the dose of S-1 was reduced by 20 mg/d.

Sample Size Determination: Statistical Methods

In the initial plan, the total target number of patients was set at 600, given a statistical power of 80%, an enrollment period of 3 years, and a follow-up period of 2 years. However, because patient enrollment was faster than expected, the target number of patients was revised to 750 to provide the study with a statistical power of 90%. Consequently, the final analysis was performed after the occurrence of 680 events had been confirmed. An interim analysis was not performed. Although the actual median OS in the gemcitabine group was better than initially expected, because an adequate number of patients had been enrolled, a power of ≥ 90% was maintained on recalculation of the power on the basis of the actual results.

Quality of Life

To assess the quality of life, the health status of patients on the EQ-5D questionnaire was converted into a single simple utility index ranging from 0 for death to 1 for complete health. Quality-adjusted life years (QALYs) for individual patients were estimated as the product of the utility index during follow-up and survival time and were compared between the groups, using the generalized Wilcoxon test.

As a result, median QALYs were 0.401 in the gemcitabine group, 0.420 in the S-1 group, and 0.525 in the GS group. The QALY value in the S-1 group was similar to that in the gemcitabine group, and there was no statistically significant difference between the two groups ($P = .56$). The QALY value in the GS group was significantly better than that in the gemcitabine group ($P < .001$). The details of quality-of-life assessments will be reported elsewhere.

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES

1

- A—AUTHOR: Please define GEST in title, footnotes, abstract, and text.
- B—AUTHOR: **You are responsible for detecting any errors in this proof.** Confirm that all dosing information and treatment regimens are complete and accurate in text, tables, and figures, if applicable to article content.
- C—AUTHOR: Please define EQ-5D.
- D—AUTHOR: Figures in your article have been edited and redrawn to conform to JCO style. **As author, it is your responsibility to review all figure content carefully and completely for accuracy, including dosing information, axis labels, and legends, if applicable.** At this advanced stage of production, changes to figures should only be made to correct data/factual errors or errors that severely compromise clarity or meaning.
- E—AUTHOR: Please verify conflicts of interest information is complete and accurate as of acceptance date.
- F—AUTHOR: Please verify that all contribution information is correct for each author.
- G—AUTHOR: This acknowledgment will appear online only. Please review copy in proofs and make any necessary corrections.
- H—AUTHOR: This Appendix will appear only online. Please review copy in proofs and make any necessary corrections.

A: GEST: Gemcitabine and S-1 Trial
B: OK
C: EQ-5D: EuroQol 5 Dimension
D: OK
E: OK
F: OK
G: OK
H: OK

Safety of UFT/LV and S-I as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial

I Mochizuki¹, H Takiuchi², K Ikejiri³, Y Nakamoto⁴, Y Kinugasa⁵, A Takagane⁶, T Endo⁷, H Shinozaki⁸, Y Takii⁹, Y Takahashi¹⁰, H Mochizuki¹¹, K Kotake¹², S Kameoka¹³, K Takahashi¹⁴, T Watanabe¹⁵, M Watanabe¹⁶, N Boku¹⁷, N Tomita¹⁸, Y Matsubara¹⁹ and K Sugihara^{*,20}

¹Department of Gastroenterological Surgery, Iwate Central Prefectural Hospital, 1-4-1 Ueda, Morioka, Iwate 020-0066, Japan; ²Cancer Chemotherapy Center, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan; ³Department of Surgery, Gastrointestinal Center, National Hospital Organization Kyushu Medical Center, 1-8-1 Jigyohama, Chuo-ku, Fukuoka 810-8563, Japan; ⁴Department of Surgery, Kobe City Medical Center West Hospital, 1-2-4 Nagata-ku, Kobe, Hyogo 653-0013, Japan; ⁵Division of Colon and Rectal Surgery, Shizuoka Cancer Center Hospital, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan; ⁶Department of Surgery, Hakodate Goryokaku Hospital, 38-3 Goryokaku-cho, Hakodate, Hokkaido 040-8611, Japan; ⁷Department of Coloproctological Surgery, Japanese Red Cross Medical Center, 4-1-22 Hiroo, Shibuya-ku, Tokyo 150-8935, Japan; ⁸Department of Surgery, Saiseikai Utsunomiya Hospital, 911-1 Takebayashi, Utsunomiya, Tochigi 321-0974, Japan; ⁹Department of Surgery, Niigata Cancer Center Hospital, 2-15-3, Kawagishi-cho, Chuo-ku, Niigata, Niigata 951-8566, Japan; ¹⁰Department of Surgery, Ogaki Municipal Hospital, 4-86 Minaminokawa-cho, Ogaki, Gifu 503-8502, Japan; ¹¹Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan; ¹²Department of Surgery, Tochigi Cancer Center, 4-9-13 Yonan, Utsunomiya, Tochigi 320-0834, Japan; ¹³Department of Surgery II, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjyuku-ku, Tokyo 162-8666, Japan; ¹⁴Department of Surgery, Cancer and Infectious Diseases Center Komagome Hospital, 18-22, Honkomagome 3-chome, Bunkyo-ku, Tokyo 113-8677, Japan; ¹⁵Department of Surgery, Teikyo University, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan; ¹⁶Department of Surgery, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagami-hara, Kanagawa 252-0375, Japan; ¹⁷Department of Clinical Oncology, St Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan; ¹⁸Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan; ¹⁹Department of Data Management and Analysis, Translational Research Informatics Center, 1-5-4 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan; ²⁰Department of Surgical Oncology, Tokyo Medical and Dental University, Graduate School, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

BACKGROUND: The Adjuvant Chemotherapy Trial of TS-I for Colon Cancer (ACTS-CC) is a phase III trial designed to validate the non-inferiority of S-I to UFT/leucovorin (LV) as postoperative adjuvant chemotherapy for stage III colon cancer. We report the results of a planned safety analysis.

METHODS: Patients aged 20–80 years with curatively resected stage III colon cancer were randomly assigned to receive UFT/LV (UFT, 300 mg m⁻² per day as tegafur; LV, 75 mg per day on days 1–28, every 35 days, 5 courses) or S-I (80, 100, or 120 mg per day on days 1–28, every 42 days, 4 courses). Treatment status and safety were evaluated.

RESULTS: Of 1535 enrolled patients, a total of 1504 (756 allocated to S-I and 748 to UFT/LV) were analysed. The completion rate of protocol treatment was 77% in the S-I group and 73% in the UFT/LV group. The overall incidence of adverse events (AEs) were 80% in S-I and 74% in UFT/LV. Stomatitis, anorexia, hyperpigmentation, and haematological toxicities were common in S-I, whereas increased alanine aminotransferase and aspartate aminotransferase were common in UFT/LV. The incidences of ≥ grade 3 AEs were 16% and 14%, respectively.

CONCLUSION: Although AE profiles differed between the groups, feasibility of the protocol treatment was good. Both S-I and UFT/LV could be safely used as adjuvant chemotherapy.

British Journal of Cancer (2012) **106**, 1268–1273. doi:10.1038/bjc.2012.86 www.bjcancer.com

Published online 13 March 2012

© 2012 Cancer Research UK

Keywords: colon cancer; adjuvant chemotherapy; phase III; S-I; UFT

Colorectal cancer (CRC) was the second most common cancer in Japan, affecting over 100 000 individuals (Cancer statistics in Japan, 2010). The Japanese Society for Cancer of the Colon and Rectum (JSCCR) reported that recurrence rates were 3.7% for stage I disease, 13.3% for stage II, and 30.8% for stage III (Kobayashi

et al, 2007). Postoperative adjuvant chemotherapy for patients with stage III CRC is now internationally accepted as a standard care to improve outcomes. In the mid-1990s, 6 months of intravenous (i.v.) therapy with 5-fluorouracil (5-FU)/leucovorin (LV) was established to be standard adjuvant chemotherapy for colon cancer. Subsequently, the benefits of adding oxaliplatin to 5-FU/LV were evaluated. At present, 5-FU/LV combined with oxaliplatin is regarded as the standard adjuvant chemotherapy for stage III colon cancer in western countries (Labianca *et al*, 2010; National comprehensive cancer network (NCCN), 2011).

*Correspondence: Dr K Sugihara; E-mail: k-sugi.srg2@tmd.ac.jp

Received 12 December 2011; revised 14 February 2012; accepted 20 February 2012; published online 13 March 2012

The JSCCR Guidelines 2010 for the Treatment of Colorectal Cancer (Japanese Society for Cancer of the Colon and Rectum, 2010) recommend four regimens as adjuvant therapy for stage III CRC: i.v. 5-FU/LV, UFT/LV, capecitabine, and FOLFOX (5-FU/LV plus oxaliplatin). However, large population database demonstrated that outcomes differ among subgroups of patients with stage III disease (Gunderson *et al*, 2010). Consequently, in Japan, considering expected benefits and possible risks of increased toxicity, a consensus has not been reached as to whether adjuvant regimens containing oxaliplatin should be given to all patients with stage III disease. Actually, in Japan, several oral 5-FU derivatives are available, and oral 5-FU agents have been preferred because of their convenience. About 80% of CRC patients received adjuvant chemotherapy using oral 5-FU agents. UFT/LV is one of the most widely used regimens for adjuvant chemotherapy of stage III CRC in Japan.

UFT (Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) is an oral 5-FU derivative that combines tegafur with uracil in a molar ratio of 1:4. Tegafur is a prodrug of 5-FU, and uracil competitively inhibits the degradation of 5-FU by dihydropyrimidine dehydrogenase (DPD). Concomitant use of the oral folic acid derivative LV with UFT promotes stabilising the ternary complex and augmenting the inhibition of thymidylate synthase (TS) by 5-FU. The National Surgical Adjuvant Breast and Bowel Project (NSABP) C-06 trial, which enrolled 1608 patients with stage II or III colon cancer in the United States, demonstrated non-inferiority of UFT/LV to i.v. 5-FU/LV in terms of efficacy and safety (Lembersky *et al*, 2006), and demonstrated better convenience of UFT/LV (Kopeck *et al*, 2007).

S-1 (TS-1; Taiho Pharmaceutical Co., Ltd) is another oral 5-FU derivative available for CRC in Japan. It combines tegafur, gimeracil, and oteracil, in a molar ratio of 1:0.4:1 (Shirasaka *et al*, 1996). Gimeracil, a DPD inhibitor, is about 200-fold more potent than uracil. Oteracil inhibits the conversion of 5-FU to active metabolites in the gastrointestinal tract, resulting in reduction of gastrointestinal toxicity of 5-FU. The phase II trial of monotherapy with S-1 for metastatic CRC showed response rates about 35%, which were higher than that of UFT/LV (Ohtsu *et al*, 2000). In a large phase III study in patients with stage II and III gastric cancer (Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC) trial), 1 year of postoperative adjuvant chemotherapy with S-1 compared with surgery alone disclosed significantly prolonged relapse-free survival and overall survival (Sakuramoto *et al*, 2007). S-1 is now widely used as the standard adjuvant chemotherapy for GC. However, the efficacy of S-1 as adjuvant chemotherapy on CRC has not been established.

S-1 has several advantages, including slightly higher anti-tumour activity, low costs, and easy administration, that is, twice daily after meals (UFT/LV is given three times daily, more than 1 h after or before meals). In addition, because of differences in the mechanisms of action, S-1 may be useful in a different subset of patients and have a distinct toxicity profile from that of UFT/LV. S-1 may thus become a new, more convenient option of adjuvant regimen.

We designed a study named ACTS-CC (ACTS for Colon Cancer) to verify the non-inferiority of S-1 to UFT/LV, and thereby confirm the usefulness of adjuvant chemotherapy with S-1 for stage III CRC (ClinicalTrials.gov: no. NCT00660894). The primary endpoint is disease-free survival rate at 3 years after finishing enrolment. Enrolment started in April 2008 and was completed in June 2009. Final conclusions regarding the therapeutic usefulness of these regimens will be open in 2012. But, safety data of UFT/LV and S-1 from large trials with CRC is still unclear, although they are now widely used clinically in Japan. We therefore report the results of a planned interim analysis limited to the safety data in this study, to contribute to the safer use of these regimens in clinical practice.

MATERIALS AND METHODS

Enrolment and assignment

This study was conducted in accordance with the 'Declaration of Helsinki' and the 'Ethical Guidelines for Clinical Research', and was approved by the Institutional Review Boards of each participating institute. Written informed consent was obtained from all patients before enrolment.

Eligible patients were centrally registered by using a Web enrolment system. The main eligible criteria were as follows: aged 20–80 years, histologically confirmed stage III colon adenocarcinoma after curative surgery, starting chemotherapy within 8 weeks after surgery, performance status of 0–1, adequate oral intake, and preserved major organ functions.

Randomisation and masking

After confirming eligibility, enrolled patients were randomly assigned to receive either UFT/LV or S-1 at the central registration centre by a computer programme, by use of a minimisation method with stratification by lymph node metastasis (N1 or N2) and institution. Assignment of patients was concealed from the investigator. Treatment assignment was not masked from the investigators or patients.

Protocol treatment

In the UFT/LV arm, UFT was given at a dose of 300 mg m⁻² per day as tegafur in three divided doses (every 8 h) more than 1 h after or before meals. A quantity of 75 mg per body per day of LV was given in three divided doses simultaneously with UFT. These drugs were orally administered for 28 consecutive days, followed by a 7-day rest. This 5-week treatment comprised one course. A total of five courses (25 weeks) were delivered.

In the S-1 arm, S-1 was orally given at a dose according to body surface area (BSA; 40 mg with BSA <1.25 m²; 50 mg with BSA 1.25–1.5 m²; 60 mg with BSA >1.5 m²) twice daily after meals for 28 consecutive days, followed by a 14-day rest. This 6-week treatment comprised one course. A total of four courses (24 weeks) were delivered.

Assigned treatment was started within 8 weeks after surgery. During protocol treatment, clinical findings and laboratory values were evaluated every 2 to 3 weeks (evaluations at the time of starting each course were mandatory). Protocol treatment in each course was started and continued when the patients fulfilled the criteria included: leukocytes ≥3000/mm³, platelets ≥100 000/mm³, haemoglobin ≥9.0 g dl⁻¹, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤100 IU l⁻¹, total bilirubin ≤2.0 mg dl⁻¹, creatinine <1.5 mg dl⁻¹, no greater than grade 1 anorexia, nausea, vomiting, and diarrhoea. If the criteria for starting/continuing treatment are not met, treatment was postponed or temporarily suspended until adverse events (AEs) had become to meet the criteria. Depending upon the severity of AEs, the dose of UFT or S-1 was reduced in accordance with the protocol when the treatment was resumed. Once the dose had been reduced, it was not to be increased at a later time. In the UFT/LV group, the dose of LV was not modified.

Protocol treatment was discontinued in the cases included: recurrence or other malignancies developed, treatment failed to be resumed within 14 days after being postponed or temporarily suspended (the pre-defined drug rest for each group is not included), further dose reduction was necessary because of AEs, and so on, even after the specified dose was reduced by two levels or to minimal dose level, the physician judged that the protocol treatment was difficult to continue, the patient requested discontinuation of protocol treatment, and the patients withdrew informed consent.

Data collection

Treatment status Physicians reported the treatment status (i.e., the number of days of administration in each course) by a Web-based case report system.

The drug compliance for each course was defined as the ratio of the actually taken dose to the prescribed dose, and was classified to the following four categories: (1) $\geq 90\%$ taken, (2) $\geq 75\%$ to $< 90\%$ taken, (3) $\geq 50\%$ to $< 75\%$ taken, and (4) $< 50\%$ taken.

Using reported information in the case report form, taken dose per course was calculated for each patient as follows: (prescribed daily dose) \times (number of days of administration) \times (oral drug compliance for each course). Relative dose intensity for each patient was defined as the ratio of cumulative taken dose during the entire treatment period to scheduled total dose per protocol.

Completion rate of protocol treatment was defined as the ratio of the number of patients who completed four courses of S-1 treatment or five courses of UFT/LV treatment to the number of patients included in the safety analysis set of each group.

Safety profile The types and severities of AEs from the start of protocol treatment to 30 days after the last administration were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (National Cancer Institute, Bethesda, MD, USA). The most severe grade of each AE during each course was reported. The following AEs were required to report as 'priority survey items': leukocytes, haemoglobin, platelets, total bilirubin, AST, ALT, creatinine, stomatitis, anorexia, nausea, vomiting, diarrhoea, rash/desquamation, hyperpigmentation, and fatigue.

Statistical analysis

Data were analysed using SAS (Statistical Analysis System) version 9.1.2 (SAS Institute Inc., Cary, NC, USA). Descriptive statistics such as means, s.d., and medians were calculated. The incidences of categorised discrete values were expressed as percentages for each group.

RESULTS

Patients' characteristics

From April 2008 through June 2009, a total of 1535 patients were enrolled from 358 hospitals in Japan. After excluding 31 patients

because of the reasons shown in Figure 1, 1504 were included in the safety analysis (756 in the S-1 group and 748 in the UFT/LV group). The data were cut off on 11 August 2010. The characteristics of the 1504 patients are shown in Table 1.

Table 1 Patients' characteristics

		S-1		UFT/LV	
		n = 756	(%)	n = 748	(%)
Age (years)	Median (range)	66 (23–80)	—	65 (32–80)	—
	≥ 70 years	279	(36.9)	252	(33.7)
Gender	Male	411	(54.4)	397	(53.1)
	Female	345	(45.6)	351	(46.9)
PS (ECOG)	0	720	(95.2)	716	(95.7)
	I	36	(4.8)	32	(4.3)
Tumour location	Right colon (C, A, T)	324	(42.9)	262	(35.0)
	Left colon (D, S)	277	(36.6)	309	(41.3)
	Rectosigmoid	155	(20.5)	177	(23.7)
Depth of tumour invasion (TNM 7th)	T1	40	(5.3)	46	(6.1)
	T2	76	(10.1)	77	(10.3)
	T3	428	(56.6)	425	(56.8)
	T4	212	(28.0)	200	(26.8)
Extent of LN dissection ^a	D1	5	(0.7)	5	(0.7)
	D2	142	(18.8)	150	(20.1)
	D3	609	(80.6)	593	(79.3)
No. of LN examined	Median (range)	18 (1–78)	—	16 (1–78)	—
	< 12	181	(24.1)	206	(27.5)
	≥ 12	575	(75.9)	542	(72.5)
LN metastasis (TNM 7th)	N1a	330	(43.7)	325	(43.4)
	N1b	265	(35.1)	263	(35.2)
	N2a	116	(15.3)	113	(15.1)
	N2b	45	(6.0)	47	(6.3)
Stage (TNM 7th)	IIIA	105	(13.9)	118	(15.8)
	IIIB	550	(72.8)	516	(69.0)
	IIIC	101	(13.4)	114	(15.2)

Abbreviations: ECOG = The Eastern Cooperative Oncology Group; LN = lymph node; LV = leucovorin; PS = performance status. D1: complete dissection of pericolic/perirectal lymph nodes D2: complete dissection of pericolic/perirectal and intermediate lymph nodes D3: complete dissection of all regional lymph nodes. ^aExtent of lymph node dissection according to Japanese Classification of Colorectal Carcinoma.




Figure 1 CONSORT diagram.